Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2016-05-19 Director's Dealing
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2016-05-19 English
10-Q
Interim / Quarterly Report Q1 2016
2016-05-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated May 12, 2016, reporting the results of operations and financial condition for the first quarter ended March 31, 2016. It specifically states that the company issued a press release announcing its financial results for the quarter, and the press release is attached as Exhibit 99.1. The document itself is short (3335 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, initial announcements of quarterly financial results with key highlights only are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2016-05-12 English
6-K
Report Publication Announcement Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 29, 2016. It announces that Adaptimmune Therapeutics plc has published its UK Annual Report and Accounts for the period ended December 31, 2015, and distributed a notice of its Annual General Meeting (AGM), a form of proxy, the UK Annual Report, and Articles of Association to shareholders. The document explicitly states that the UK Annual Report is available on the company's website and is not filed as part of this report. The document itself is short (4839 characters) and primarily serves as an announcement of the publication and distribution of the Annual Report and AGM notice, rather than containing the full Annual Report or detailed financial data. Therefore, according to the MENU VS MEAL RULE, this document is an announcement of the report and AGM materials, not the report itself. The document also includes the notice of the AGM as an exhibit, but the main content is the announcement of these materials. Hence, the appropriate classification is Report Publication Announcement (RPA).
2016-04-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 22, 2016. It reports "Other Events" under Item 8.01, specifically mentioning a press release summarizing clinical and corporate highlights presented at the company's Investor and Analyst Day. The document itself is short (3512 characters) and primarily references an attached press release (Exhibit 99.1). There is no substantive financial data or detailed report content within this filing; it is an announcement of an event and a press release. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not fit into more specific categories like Investor Presentation or Earnings Release. The document is not the full report or presentation itself, but a filing to notify the market of the event and release.
2016-04-22 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated April 22, 2016. It includes disclosures under Item 7.01 (Regulation FD Disclosure) about a live audio webcast and an attached slide presentation for the Investor and Analyst Day 2016. The document also includes press releases about the appointment of a scientific advisory board and a naming announcement for proprietary technology. The key content is the slide presentation for the Investor and Analyst Day, which is a detailed presentation for investors focusing on financials, strategy, and market position. The document is about 5242 characters, which is sufficient to contain substantive content rather than just an announcement. Therefore, the most appropriate classification is Investor Presentation (IP).
2016-04-22 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.